[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Kim GM, Jeung HC, Kim D, Kim JH, Yoon SH, Jung ES, Shin SJ: A case of combined hepatocellular-cholangiocarcinoma with favorable response to systemic chemotherapy. Cancer Res Treat; 2010 Dec;42(4):235-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of combined hepatocellular-cholangiocarcinoma with favorable response to systemic chemotherapy.
  • Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary liver cancer composed of cells with histopathologic features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC).
  • Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC.
  • We report a case of cHCC-CC exhibiting a favorable response to systemic chemotherapy with doxorubicin and cisplatin.
  • A 62-year-old man who recurred after a right lobectomy for cHCC-CC received sorafenib for palliative systemic therapy, but follow up imaging studies showed disease progression.
  • He received 2nd line chemotherapy with doxorubicin at 60 mg/m(2) together with cisplatin at 70 mg/m(2).
  • After 2 cycles of chemotherapy, a computed tomography scan of the chest showed markedly decreased size and number of the multiple lung metastases.
  • After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin.
  • To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Rinsho. 2001 Oct;59 Suppl 6:401-5 [11761981.001]
  • [Cites] Ann Surg Oncol. 2009 Mar;16(3):623-9 [19130133.001]
  • [Cites] Gut. 2002 May;50(5):733-9 [11950826.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jun;33(6):283-7 [12913082.001]
  • [Cites] Am J Surg. 2005 Jan;189(1):120-5 [15701504.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(6):537-42 [17139428.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Aug;11(8):758-64 [8872774.001]
  • [Cites] Hepatol Res. 2005 May;32(1):52-7 [15888382.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(12):1941-3 [17212153.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1500-4 [17461440.001]
  • [Cites] Asian J Surg. 2007 Apr;30(2):143-6 [17475587.001]
  • [Cites] Am J Pathol. 1949 Jul;25(4):647-55 [18152860.001]
  • [Cites] Int J Clin Pract. 2008 Aug;62(8):1271-8 [18284443.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • (PMID = 21253326.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3021743
  • [Keywords] NOTNLM ; Cholangiocarcinoma / Cisplatin / Doxorubicin / Hepatocellular carcinoma
  •  go-up   go-down


2. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD: Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer; 2004 Aug 1;101(3):578-86
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
  • BACKGROUND: The goal of the current study was to evaluate the efficacy and toxicity of capecitabine in patients with nonresectable hepatobiliary carcinoma.
  • METHODS: The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine.
  • The medical records of 116 patients with hepatobiliary carcinoma who were treated at The University of Texas M. D.
  • Capecitabine 1000 mg/m(2) was administered twice daily for 14 days.
  • Treatment was repeated every 21 days.
  • Each patient received 1-15 treatment cycles.
  • A CR was radiologically confirmed in one patient with HCC and in two patients with GBC.
  • The median survival times were 10.1 months (95% confidence interval [CI], 4.5-15.7 months) for patients with HCC, 8.1 months (95% CI, 7.4-8.9 months) for patients with CCA, and 9.9 months (95% CI, 4.4-15.4 months) for patients with GBC.
  • For all patients, response to treatment was positively correlated with survival and decline in tumor markers.
  • CONCLUSIONS: Capecitabine was found to be safe for patients with hepatobiliary carcinoma, including those with cirrhosis.
  • The antitumor activity of single-agent capecitabine was most pronounced in patients with GBC, was modest in patients with HCC, and was poor in patients with CCA.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / drug therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Bile Ducts, Intrahepatic. Capecitabine. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / analogs & derivatives. Follow-Up Studies. Humans. Male. Multivariate Analysis. Probability. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome


3. Verslype C, Prenen H, Van Cutsem E: The role of chemotherapy in biliary tract carcinoma. HPB (Oxford); 2008;10(3):164-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapy in biliary tract carcinoma.
  • Cholangiocarcinoma is a rare malignancy associated with poor prognosis and high mortality.
  • There are no well-conducted studies regarding the role of adjuvant chemotherapy.
  • Preliminary data suggest that liver transplantation could offer long-term survival in selected patients when combined with neoadjuvant chemoradiotherapy.
  • The literature regarding treatment results with specific regimens in the adjuvant setting is limited and no general recommendation can be given.
  • In patients with locally advanced or metastatic disease, most studies are small, non-randomized phase II trials, and many studies comprise a mix of bile duct cancers, gallbladder cancer, and either pancreatic or hepatocellular cancers.
  • In metastatic cancer, phase II studies with several cytotoxics, including gemcitabine, the platinums, and the fluoropyrimidines, have shown a modest and often short-lasting activity.
  • No single chemotherapy agent or combination regimen can therefore be recommended as a standard of care at present.
  • In this review, we give an overview of chemotherapy in the adjuvant, neoadjuvant, and advanced settings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):309-15 [18182984.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):425-8 [10955877.001]
  • [Cites] Oncology. 2007;72(1-2):105-10 [18025804.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):734-40 [17968163.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1307-12 [17628484.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3069-74 [16809731.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1339-46 [16475213.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61 [16135931.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1650-4 [15856037.001]
  • [Cites] Jpn J Clin Oncol. 2005 Feb;35(2):68-73 [15709089.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):398-403 [15691639.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1769-74 [15505626.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] Anticancer Drugs. 1998 Jun;9(5):393-7 [9660535.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Eur J Cancer. 1993;29A(5):698-703 [8471327.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):478-83 [14998852.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1192-6 [12181241.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):985-93 [11910351.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1403-6 [11762811.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):783-9 [11462924.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):99-103 [17846018.001]
  • (PMID = 18773046.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2504367
  •  go-up   go-down


Advertisement
4. Jarnagin WR, Schwartz LH, Gultekin DH, Gönen M, Haviland D, Shia J, D'Angelica M, Fong Y, Dematteo R, Tse A, Blumgart LH, Kemeny N: Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol; 2009 Sep;20(9):1589-95
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.
  • BACKGROUND: This study reports the results of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (dex) in patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) and investigates dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) assessment of tumor vascularity as a biomarker of outcome.
  • Radiologic dynamic and pharmacokinetic parameters related to tumor perfusion were analyzed and correlated with response and survival.
  • RESULTS: Partial responses were seen in 16 patients (47.1%); time to progression and response duration were 7.4 and 11.9 months, respectively.
  • DCE-MRI data showed that patients with pretreatment integrated area under the concentration curve of gadolinium contrast over 180 s (AUC 180) >34.2 mM.s had a longer median survival than those with AUC 180 <34 mM.s (35.1 versus 19.1 months, P = 0.002).
  • Decreased volume transfer exchange between the vascular space and extracellular extravascular space (-DeltaK(trans)) and the corresponding rate constant (-Deltak(ep)) on the first post-treatment scan both predicted survival.
  • CONCLUSIONS: In patients with unresectable primary liver cancer, HAI therapy can be effective and safe.
  • Pretreatment and early post-treatment changes in tumor perfusion characteristics may predict treatment outcome.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Rev. 1951 Mar;3(1):1-41 [14833874.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] J Am Coll Surg. 2005 Jul;201(1):57-65 [15978444.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4888-96 [16009951.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7041-4 [16103049.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):853-8 [16611778.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):409-14 [16633367.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3069-74 [16809731.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3293-8 [16829653.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] NMR Biomed. 2007 Apr;20(2):128-40 [17006886.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3449-59 [17575207.001]
  • [Cites] JAMA. 2008 Apr 9;299(14):1669-77 [18398079.001]
  • [Cites] Magn Reson Med. 2008 May;59(5):1183-9 [18429032.001]
  • [Cites] Ann Surg. 2008 Jul;248(1):84-96 [18580211.001]
  • [Cites] Cancer Lett. 2008 Aug 18;267(1):26-36 [18420342.001]
  • [Cites] NMR Biomed. 2002 Apr;15(2):154-63 [11870911.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2039-48 [10615075.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Br J Radiol. 1999 Nov;72(863):1093-8 [10700827.001]
  • [Cites] Ann Surg Oncol. 2000 Sep;7(8):593-600 [11005558.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2513-6 [11289123.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1353-7 [11391522.001]
  • [Cites] NMR Biomed. 2002 Apr;15(2):132-42 [11870909.001]
  • [Cites] Angiogenesis. 2001;4(3):163-73 [11911014.001]
  • [Cites] Surgery. 2002 Apr;131(4):433-42 [11935134.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3955-64 [14517187.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3650-7 [15173071.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Cancer Res. 1978 Nov;38(11 Pt 1):3784-92 [151583.001]
  • [Cites] Physiol Chem Phys Med NMR. 1984;16(2):167-72 [6505043.001]
  • [Cites] Magn Reson Med. 1991 Feb;17(2):357-67 [2062210.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):920-4 [1370918.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):330-5 [8426211.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • (PMID = 19491285.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21CA121553-01A1
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; 7S5I7G3JQL / Dexamethasone
  • [Other-IDs] NLM/ PMC2731015
  •  go-up   go-down


5. Shimoda M, Kubota K: Multi-disciplinary treatment for cholangiocellular carcinoma. World J Gastroenterol; 2007 Mar 14;13(10):1500-4
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-disciplinary treatment for cholangiocellular carcinoma.
  • Cholangiocarcinoma (CC) is rare malignant tumors composed of cells that resemble those of the biliary tract.
  • It is notoriously difficult to diagnose, and is associated with a high mortality.
  • Traditionally, CC is divided into intrahepatic and extrahepatic disease according to its location within the biliary tree.
  • Intrahepatic cholangiocellular carcinoma (IH-CCC) or peripheral cholangiocellular carcinoma (CCC) appears within the second bifurcation of hepatic bile duct, and is the second most common primary liver cancer following hepatocellular carcinoma (HCC), IH-CCC or peripheral CCC often presents with advanced clinical features, and the cause for this cancer rise is still unclear.
  • Liver transplantation could offer long-term survival in selected patients when combined with chemotherapy.
  • Chemotherapy, radiation therapy or combination therapies remain as the only treatment for inoperable patients.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / therapy
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy. Hepatectomy. Humans. Kaplan-Meier Estimate. Liver Transplantation. Radiotherapy. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Surg Oncol. 1993 Jul-Aug;9(4):298-304 [8210909.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):31-8 [1309988.001]
  • [Cites] Semin Liver Dis. 1994 May;14(2):109-14 [8047893.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):788-97; discussion 797-8 [7794082.001]
  • [Cites] Hepatogastroenterology. 1995 Jul;42(3):265-8 [7590576.001]
  • [Cites] World J Surg. 1995 Nov-Dec;19(6):807-13 [8553670.001]
  • [Cites] Gut. 1996 Apr;38(4):610-5 [8707097.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):628-38 [8916878.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):429-36 [9358085.001]
  • [Cites] Hepatology. 1997 Nov;26(5):1176-81 [9362359.001]
  • [Cites] Am J Surg. 1997 Dec;174(6):605-8; discussion 608-9 [9409582.001]
  • [Cites] J Am Coll Surg. 1998 Oct;187(4):358-64 [9783781.001]
  • [Cites] Hepatology. 1999 Apr;29(4):1099-105 [10094953.001]
  • [Cites] AMA Arch Surg. 1957 Sep;75(3):450-60; discussion 460-1 [13457619.001]
  • [Cites] Am J Med. 1965 Feb;38:241-56 [14256720.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] World J Surg. 2005 Jun;29(6):728-33 [15880276.001]
  • [Cites] Can J Gastroenterol. 2005 Dec;19(12):711-6 [16341310.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):127-31 [16601429.001]
  • [Cites] Ann Surg. 2000 Aug;232(2):166-74 [10903592.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2001 Aug;15(4):643-56 [11492973.001]
  • [Cites] Am Surg. 2001 Sep;67(9):839-43; discussion 843-4 [11565760.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1463-6 [11683741.001]
  • [Cites] Liver Transpl. 2001 Dec;7(12):1023-33 [11753904.001]
  • [Cites] Arch Surg. 2002 Jan;137(1):69-73 [11772220.001]
  • [Cites] J Hepatol. 2002 Mar;36(3):321-7 [11867174.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):351-6 [12201499.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Oct;11(4):955-68 [12607582.001]
  • [Cites] Ann Surg. 2003 May;237(5):686-91; discussion 691-3 [12724635.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(4):288-91 [14598147.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):189-99 [15192791.001]
  • [Cites] Am Surg. 2004 Sep;70(9):743-8; discussion 748-9 [15481288.001]
  • [Cites] Surg Clin North Am. 1985 Feb;65(1):59-78 [3887621.001]
  • [Cites] Surg Clin North Am. 1990 Dec;70(6):1429-47 [2174191.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):2051-5 [1717133.001]
  • [Cites] Am J Surg. 1993 Dec;166(6):768-71; discussion 771-2 [8273866.001]
  • (PMID = 17461440.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 37
  • [Other-IDs] NLM/ PMC4146890
  •  go-up   go-down


6. Yamamoto N, Murata K, Fuke H, Inoue T, Yamanaka Y, Saitou Y, Ito K, Sugimoto K, Koyama M, Shiraki K, Nakano T: Macrocytic anemia during low-dose cisplatin and 5-Fluorouracil through implanted infusion port for unresectable hepatobilliary malignancies. Anticancer Res; 2005 Mar-Apr;25(2B):1243-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The efficacy of continuous arterial infusion chemotherapy through a subcutaneously implanted port has been reported with less adverse effects than systemic chemotherapy in hepatobilliary malignancies.
  • However, macrocytic anemia is sometimes seen during this therapy.
  • In 25 patients (22 with hepatocellular carcinoma, 3 with cholangiocellular carcinoma) treated with cisplatinum (10mg/day) and 5-Fluorouracil (5-FU) (250 mg/day), the frequency of anemia and its etiologies were evaluated.
  • Moreover, the two groups ("anemia" and "no anemia" group) were compared with their backgrounds.
  • Nine cases (36%) showed macrocytic anemia without any evident etiologies during therapy.
  • The Child-Pugh score or Japanese integrated staging (JIS) score were significantly higher in the "anemia" group than that in the "no anemia" group.
  • CONCLUSION: Attention should be paid to slow progressive macrocytic anemia during low-dose cisplatinum and 5-FU, especially in patients with advanced liver cirrhosis.
  • [MeSH-major] Anemia, Macrocytic / epidemiology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bile Duct Neoplasms / drug therapy. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Aged. Humans. Infusion Pumps, Implantable. Liver Cirrhosis / complications

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865072.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


7. Noda T, Nagano H, Marubashi S, Kobayashi S, Takeda Y, Murakami M, Tomimaru Y, Dono K, Umeshita K, Nakayama M, Shima T, Wakasa K, Monden M, Doki Y, Mori M: [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2099-102
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy].
  • We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy.
  • A 63-year-old female was in hospital for treatment of hepatic tumor in left lobe with portal venous tumor thrombus.
  • She was treated by IFN-alpha/5-FU chemotherapy, and the tumor was significantly reduced.
  • For 28 months, the tumor was successfully treated by IFN-alpha/5-FU chemotherapy.
  • But, thereafter the abdominal computed tomography showed the tumor re-growth and invasion to the diaphragm.
  • Then the patient underwent the tumor resection.
  • The histological findings were consistent with combined hepatocellular and cholangiocarcinoma.
  • This case suggested that the growth of cancer cells without sensitivity to IFN-alpha/5-FU chemotherapy and the blood supply via the diaphragm led the relapse of IFN-alpha/5-FU chemotherapy.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / drug therapy. Diaphragm / pathology. Fluorouracil / therapeutic use. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy. Muscle Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Neoplasm Invasiveness / pathology. Tomography, X-Ray Computed. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106536.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / alpha-Fetoproteins; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Hatano H, Kobayashi S, Nagano H, Tomokuni A, Tomimaru Y, Murakami M, Marubashi S, Eguchi H, Takeda Y, Tanemura M, Wakasa K, Doki Y, Mori M: [A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2374-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
  • We report a case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus.
  • A 66-year-old man was diagnosed with hepatocellular carcinoma with Vp3 by abdominal enhanced CT.
  • He underwent a complete tumor resection and following interferon and 5-FU combined intra-arterial chemotherapy as an adjuvant setting.
  • The histological findings were consistent with combined hepatocellular and cholangiocarcinoma.
  • At 9 months after the surgery, lymph node metastases were detected.
  • Then we started an oral fluoropyrimidine anticancer agent S-1, because the recurrence was suspected to be originated from the cholangiocarcinoma component.
  • In case of combined hepatocellular and cholangiocarcinoma, we need to create a treatment strategy against characteristics of both components.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / therapy. Liver Neoplasms / therapy. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Drug Combinations. Fluorouracil / administration & dosage. Hepatectomy. Humans. Interferons / administration & dosage. Male. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037427.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 9008-11-1 / Interferons; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Hayashi H, Beppu T, Ishiko T, Mizumoto T, Masuda T, Okabe K, Baba Y, Okabe H, Takamori H, Kanemitsu K, Hiroto M, Baba H: [A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1941-3
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].
  • Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare type of liver cancer.
  • We herein report a case of HCC-CC with lymph node metastases treated by multimodality therapy.
  • A 52-year-old man with a 9 cm diameter mass lesion in the liver was admitted to our hospital.
  • The tumor was diagnosed as peripheral type of cholangiocarcinoma.
  • An accumulation pattern of lipiodol after TACE and an increase of serum alpha-fetoprotein led us to diagnosis of combined HCC-CC.
  • A three segmentectomies of the liver and dissection of the local lymph nodes were performed.
  • A histological examination of the resected specimen showed combined HCC-CC with lymph node metastases.
  • The final diagnosis was a mixed type of combined HCC-CC.
  • To improve a poor prognosis of combined HCC-CC, adjuvant chemotherapy with CDDP, 5 FU and radiation therapy were achieved.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / therapy. Liver Neoplasms / therapy. Lymphatic Metastasis. Neoplasms, Multiple Primary / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemoembolization, Therapeutic. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Hepatectomy. Humans. Immunohistochemistry. Keratin-19 / analysis. Keratin-7 / analysis. Lymph Node Excision. Middle Aged. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212153.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Keratin-19; 0 / Keratin-7; 0 / alpha-Fetoproteins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Eguchi H, Nagano H, Sakon M, Miyamoto A, Kondo M, Arai I, Morimoto O, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M: A successful resection and long-term survival of a patient with intrahepatic recurrences of combined hepatocellular-cholangiocarcinoma: report of a case. Surg Today; 2002;32(8):742-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A successful resection and long-term survival of a patient with intrahepatic recurrences of combined hepatocellular-cholangiocarcinoma: report of a case.
  • Because of the low incidence rate of combined hepatocellular-cholangiocarcinoma (combined HCC-CC), the clinicopathological features of a recurrent tumor of this disease remain to be elucidated.
  • We describe a 47-year-old Japanese woman with a 5-cm diameter mass lesion in the liver.
  • A hepatectomy and dissection of the local lymph nodes were performed and a histological examination of the resected specimen showed combined HCC-CC.
  • After a follow-up of 15 months, intrahepatic recurrence was observed, and a hepatectomy was performed again followed by hepatic arterial infusion chemotherapy.
  • A disease-free survival was obtained for about 7 years after the recurrence.
  • To improve the poor prognosis of combined HCC-CC, clinicopathological features of this disease and the therapy selection for recurrent tumors should be discussed.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Female. Hepatectomy. Humans. Middle Aged. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12181730.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Shimizu J, Hayashi S, Dono K, Yasumoto T, Zenitani M, Munakata K, Watanabe N, Takamoto K, Kagawa Y, Hata T, Kawanishi K, Ikeda K, Fujita J, Akagi K, Kitada M, Shimano T: [A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2380-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT].
  • Primary liver cancer with lymph node metastasis was recognized as poor prognosis.
  • We herein report a case of post operative lymph node recurrence treated with UFT.
  • A 74-year-old man with a huge mass lesion in the right liver with para Aortic lymph node metastasis admitted our hospital in April 2007.
  • Extended right lobe hepatectomy and lymph node dissection were performed in May.
  • A histological examination of the resected specimen showed a combined hepatocellular-cholangiocarcinoma with three lymph node metastasis.
  • Computed tomography(CT)revealed intra hepatic metastasis (S3) and right adrenal grand metastasis 5 months after surgery.
  • Transarterial embolization (TAE) and right adrenalectomy were performed for each metastasis.
  • CT revealed a lymph node metastasis at the right side of infra vena cava 1 year after surgery.
  • He was treated by oral administration of UFT (200 mg/day).
  • The AFP and PIVKA-II value gradually decreased after administration of UFT.
  • The size of lymph node metastasis became small confirmed by CT.
  • But the AFP and PIVKA-II value increased 1 year and 7 months after surgery.
  • TAE was performed against lymph node metastasis 1 year and 9 months after surgery.
  • This case suggests UFT is useful for suppressing the growth of the lymph node metastasis.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Embolization, Therapeutic. Humans. Male. Neoplasm Recurrence, Local. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037429.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


12. Liu S, Wang N, Yao H, Jiang N, Lu X: Preparation and identification of monoclonal antibody against human hepatocellular carcinoma with a novel immunization. Hybridoma (Larchmt); 2009 Feb;28(1):43-50
MedlinePlus Health Information. consumer health - Immunization.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preparation and identification of monoclonal antibody against human hepatocellular carcinoma with a novel immunization.
  • The purpose of this study was to prepare and identify a novel monoclonal antibody (MAb) against human primary hepatocellular carcinoma (PHC) with high specificity and activity.
  • The hepatocellular carcinoma cell line HepG2 was used to immunize BALB/c mice for preparing MAb with the classic hybridoma production technique.
  • Tail vein injection immunization combined with intrasplenic injection was applied for improvement.
  • Immunoperoxidase staining studies showed that the MAb was reactive to HepG2 and another hepatocellular carcinoma cell line, SMMC7721, 98.5% (67/68) specimens of hepatocellular carcinoma, but not to normal human liver tissues and tissues derived from the other malignant tumors, except one of the five specimens of cholangiocarcinoma with dubious staining.
  • Laser confocal scanning microscope (LCSM) analysis indicated that the MAb reacted with the whole cell, including the membrane fractions and the cytoplasm.
  • It was concluded that this combined immunization can effectively produce highly specific MAb against PHC, and this MAb may be of potential use as a targeting agent for radionuclide therapy and chemotherapy for hepatocellular carcinoma.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / isolation & purification. Carcinoma, Hepatocellular / immunology. Immunization / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19239369.001).
  • [ISSN] 1557-8348
  • [Journal-full-title] Hybridoma (2005)
  • [ISO-abbreviation] Hybridoma (Larchmt)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin M
  •  go-up   go-down


13. Bhagat V, Javle M, Yu J, Agrawal A, Gibbs JF, Kuvshinoff B, Nava E, Iyer R: Combined hepatocholangiocarcinoma: case-series and review of literature. Int J Gastrointest Cancer; 2006;37(1):27-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined hepatocholangiocarcinoma: case-series and review of literature.
  • BACKGROUND AND AIM: Combined hepatocholangiocarcinoma (CHCC) is an infrequent primary hepatic malignancy with no clearly defined diagnostic criteria, poorly studied natural history, and no guidelines regarding therapy.
  • METHODS AND RESULTS: We performed a retrospective review of all CHCC cases at our institute over the last 10 yr.
  • Eight cases were identified; histological and immunohistochemical criteria used for diagnosis were defined.
  • Abdominal pain (n = 6), hepatomegaly (n = 4), and elevated CA 19-9 >40 U/mL (n = 4/5) were frequent.
  • Early TNM stage (I and II) compared with advanced disease (III and IV) correlated with higher overall survival on univariate analyses [37 and 6 mo respectively (p = 0.011)].
  • Median overall survival was significantly higher in patients who underwent potentially curative resection (23 mo, range 4-48+) compared with patients who underwent non-surgical therapies such as transcatheter arterial chemoembolization and chemotherapy (2 mo, range 1-8) (p = 0.0357, one-sided exact log-rank test).
  • Surgical resection and early stage at diagnosis predict longer survival.
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Cholangiocarcinoma / complications. Liver Neoplasms / complications
  • [MeSH-minor] Aged. Aged, 80 and over. CA-19-9 Antigen / blood. Cholelithiasis / epidemiology. Female. Hepatitis B, Chronic / epidemiology. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1996 Oct;149(4):1167-75 [8863666.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Aug;11(8):758-64 [8872774.001]
  • [Cites] J Hepatol. 2004 Aug;41(2):292-8 [15288479.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):86-90 [12511158.001]
  • [Cites] Surg Clin North Am. 1999 Feb;79(1):43-57, viii [10073181.001]
  • [Cites] Liver. 1995 Feb;15(1):9-15 [7539881.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):643-57 [15062666.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):742-8 [9630182.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] Histopathology. 1989 May;14(5):503-13 [2472345.001]
  • [Cites] Natl Toxicol Program Tech Rep Ser. 2000 Jul;491:1-412 [12563349.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jun;33(6):283-7 [12913082.001]
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1157-62 [15788587.001]
  • [Cites] Korean J Gastroenterol. 2004 Jan;43(1):56-60 [14745254.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 1992 Feb 25;52(2):155-63 [1313961.001]
  • [Cites] Liver. 2002 Feb;22(1):43-50 [11906618.001]
  • [Cites] Jpn J Cancer Res. 1996 Oct;87(10):1056-62 [8957064.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):35-41 [11748452.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1487-90 [12397714.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):965-6 [10580599.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1978 Jun;9(2):215-9 [214874.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;31 Suppl:S38-44 [1333907.001]
  • [Cites] Natl Toxicol Program Tech Rep Ser. 2002 May;(504):1-357 [12087420.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Jan;13(1):34-40 [9737569.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):472-7 [15123362.001]
  • [Cites] J Agric Food Chem. 2000 Aug;48(8):3620-32 [10956160.001]
  • [Cites] Am J Surg. 2005 Jan;189(1):120-5 [15701504.001]
  • [Cites] Chir Ital. 1999 Jan-Feb;51(1):1-7 [10514910.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):738-43 [11710692.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1992 Jun;30(6):342-5, 382 [1337514.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] J Hepatol. 2004 Feb;40(2):298-304 [14739102.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):989-97 [12170085.001]
  • [Cites] Gan To Kagaku Ryoho. 1993 Feb;20(2):295-8 [8382037.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):191-211, v [15831268.001]
  • (PMID = 17290078.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  • [Number-of-references] 37
  •  go-up   go-down


14. Poggi G, Pozzi E, Riccardi A, Tonini S, Montagna B, Quaretti P, Tagliaferri B, Sottotetti F, Baiardi P, Pagella C, Minoia C, Bernardo G: Complications of image-guided transcatheter hepatic chemoembolization of primary and secondary tumours of the liver. Anticancer Res; 2010 Dec;30(12):5159-64
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of image-guided transcatheter hepatic chemoembolization of primary and secondary tumours of the liver.
  • BACKGROUND: Image-guided transcatheter hepatic chemoembolization (TACE) is accepted worldwide as an effective treatment for patients with unresectable hepatocellular carcinoma (HCC) and for adequate preservation of liver function.
  • Although considered relatively safe, TACE has been associated with several complications.
  • The aim of this study was to determine the prevalence of the complications associated with TACE therapy and to correlate it with certain risk factors, either well-known or not yet evaluated.
  • PATIENTS AND METHODS: A total of 330 chemoembolization procedures performed in 170 patients (117 males and 53 females) over a period of 64 months were retrospectively analysed.
  • Among the patients, 123 had hepatocellular carcinoma, 10 had intrahepatic cholangiocarcinoma and 37 had hepatic metastases.
  • The variables considered were: tumour histotype, bilioenteric anastomosis, previous or combined treatment with radiofrequency thermal ablation, antibiotic prophylaxis, chemotherapeutic agents, use of new drug-eluting microspheres, comorbidities such as diabetes, patient age and the presence of vascular anatomical variations.
  • The total complication rate per procedure was 9.1% and approximately 75% of patients had postembolization syndrome.
  • The difference in the prevalence of complications was statistically significant in the group of diabetic patients (13.3%) compared to the remaining patients (6.3%) (p = 0.002) and in patients with biliary stents (25%) compared to those without stents (7.75%) (p = 0.027).
  • The use of new drug-eluting microspheres did not increase the risk of complications.
  • [MeSH-major] Carcinoma, Hepatocellular / secondary. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / adverse effects. Liver Neoplasms / secondary. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Catheterization / adverse effects. Catheterization / methods. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187505.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Cannavó SP, Borgia F, Adamo B, Guarneri B: Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome? J Am Acad Dermatol; 2008 Apr;58(4):657-60
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome?
  • The outbreak of disseminated superficial porokeratosis during the development of solid organ malignancies has been rarely reported in the literature in patients affected by hepatitis C virus-related hepatocellular carcinoma or by cholangiocarcinoma, which suggests a paraneoplastic nature of the cutaneous disease.
  • We report an unusual case of disseminated superficial porokeratosis in a patient affected by ovarian cancer, characterized by simultaneous onset and a parallel course of the two pathologies; there was good clinical response to chemotherapy, accompanied by a successful stop of disseminated superficial porokeratosis progression and gradual clearing of the keratotic lesions.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18258333.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tsumura T, Takaki S, Aikata H, Kimura Y, Katamura Y, Azakami T, Kawaoka T, Tsuge M, Sanetou H, Waki K, Hiramatsu A, Imamura M, Kawakami Y, Takahashi S, Arihiro K, Chayama K: [Case of double cancer of the liver, cholangiocarcinoma and hepatocellular carcinoma detected in a patient with hepatitis C 13 years after diminution of HCV-RNA by interferon treatment]. Nihon Shokakibyo Gakkai Zasshi; 2009 May;106(5):674-83
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of double cancer of the liver, cholangiocarcinoma and hepatocellular carcinoma detected in a patient with hepatitis C 13 years after diminution of HCV-RNA by interferon treatment].
  • A 56-year-old man with chronic hepatitis C (HCV) was treated with interferon therapy and achieved sustained virological response (SVR) in 1993.
  • Thirteen years later, in 2006 two liver tumors, 35-mm and 11-mm in diameter respectively, were detected in liver segment 6.
  • Hepatic resection was performed, and pathologically one nodule was diagnosed as cholangiocellular carcinoma (CCC) and the other hepatocellular carcinoma (HCC).
  • Continuity was not recognized between these tumors, thus, we diagnosed this case as double cancer (CCC and HCC).
  • Here, we report a rare case of double cancer (CCC and HCC) that developed 13 years after achieving SVR for HCV infection.
  • [MeSH-major] Carcinoma, Hepatocellular. Cholangiocarcinoma. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / drug therapy. Interferon-alpha / administration & dosage. Liver Neoplasms. Neoplasms, Multiple Primary
  • [MeSH-minor] Biomarkers / blood. Hepacivirus / genetics. Humans. Male. Middle Aged. RNA, Viral / blood. Time Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis C (HCV).
  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19420872.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Interferon-alpha; 0 / RNA, Viral
  •  go-up   go-down


17. Ota H, Nagano H, Doki Y, Sekimoto M, Kondo M, Wada H, Nakamura M, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M, Monden M: Expression of type I interferon receptor as a predictor of clinical response to interferon-alpha therapy of gastrointestinal cancers. Oncol Rep; 2006 Aug;16(2):249-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of type I interferon receptor as a predictor of clinical response to interferon-alpha therapy of gastrointestinal cancers.
  • Interferon (IFN) is used in the treatment of many malignancies and viral disorders.
  • We recently reported a significant correlation between the efficacy of IFN-alpha combined with chemotherapy in the treatment of advanced hepatocellular carcinoma (HCC) and IFN-alpha/type I IFN receptor (IFNAR2) expression.
  • It is possible that the expression of IFNAR2 in gastrointestinal cancerous tissue, apart from HCC, may predict the efficacy of IFN-alpha combination therapy.
  • We investigated the expression of IFNAR2 in 100 gastrointestinal cancerous tissues.
  • IFNAR2 expression was examined using immunohistochemistry, in surgically resected tissue samples (20 esophageal, 20 gastric, 20 colorectal, 20 cholangiocarcinoma, and 20 pancreatic samples).
  • The expression rate of IFNAR2 was 35.0% (7/20), 25.0% (5/20), 20.0% (4/20), 45.0% (9/20), and 25.0% (5/20) in esophageal, gastric cancer, colorectal, cholangiocarcinoma and pancreatic cancer samples, respectively.
  • Thus, the expression rates of IFNAR2 in the five types of gastrointestinal cancers tested here were low, compared with HCC.
  • The clinical efficacy of IFN-alpha mono- or combination therapies in patients with gastrointestinal neoplasms is expected to be lower than in patients with HCC based on the expression level of IFNAR2.
  • [MeSH-major] Gastrointestinal Neoplasms / drug therapy. Interferon-alpha / therapeutic use. Membrane Proteins / analysis. Receptors, Interferon / analysis
  • [MeSH-minor] Humans. Immunohistochemistry. Prognosis. Receptor, Interferon alpha-beta. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820899.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / IFNAR2 protein, human; 0 / Interferon-alpha; 0 / Membrane Proteins; 0 / Receptors, Interferon; 156986-95-7 / Receptor, Interferon alpha-beta
  •  go-up   go-down


18. Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, Arase Y, Murashima N, Chayama K, Kumada H: Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer; 2000 Jun 1;88(11):2471-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis.
  • BACKGROUND: Hepatitis C virus (HCV) infection is a major risk factor for the development of hepatocellular carcinoma.
  • However, the risk factors for primary cholangiocellular carcinoma of the liver (PCC-L) have not been fully investigated.
  • METHODS: Between 1980 and 1997, the authors prospectively studied 600 consecutive patients for the appearance of PCC-L; these patients were positive for HCV and later developed cirrhosis.
  • RESULTS: During the observation period, PCC-L developed in 14 patients (2.3%).
  • Among these, 11 (1.8%) had cholangiocellular carcinomas and the other 3 (0.5%) had a combined type of hepatocellular and cholangiocellular carcinoma.
  • Within the same period, hepatocellular carcinoma (HCC) developed in 206 patients (34.3%).
  • The cumulative rates of newly diagnosed PCC-L were 1.6% at 5 years and 3.5% at 10 years, which was about 1000 times higher than the estimated incidence of PCC-L in the general population of Japan.
  • However, the other 11 patients received palliative therapy or chemotherapy.
  • 6%, and 16.5% at the end of 1, 3, and 5 years, respectively, and were significantly lower than those of HCC (P = 0.0001).
  • CONCLUSIONS: The results of this study show a relatively high incidence of PCC-L in patients with HCV-related cirrhosis, and also show that this type of liver cancer is associated with a relatively poor prognosis.
  • [MeSH-major] Cholangiocarcinoma / epidemiology. Hepacivirus. Liver Cirrhosis / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / virology. Female. Humans. Japan / epidemiology. Male. Middle Aged. Prospective Studies. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10861422.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


19. Donckier V, Troisi R, Toungouz M, Colle I, Van Vlierberghe H, Jacquy C, Martiat P, Stordeur P, Zhou L, Boon N, Lambermont M, Schandené L, Van Laethem JL, Noens L, Gelin M, de Hemptinne B, Goldman M: Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transpl Immunol; 2004 Sep-Oct;13(2):139-46
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
  • BACKGROUND AND AIM OF THE STUDY: The induction of transplantation tolerance, defined as the survival of a functioning allograft in the absence of continuing immunosuppressive therapy, would be a major advance.
  • We investigated the feasibility and safety of a protocol to induce tolerance to HLA mismatched living-donor liver graft by pre-transplant non-myeloablative conditioning followed by donor stem cells (SC) infusion, in patients with advanced liver cancers.
  • PATIENTS AND METHODS: Two patients with intrahepatic cancers who did not fulfill criteria for cadaver liver transplantation were included in the study.
  • Living-donor liver transplantation (LDLT) using the liver right lobe was performed after hematological reconstitution, respectively 40 and 55 days after donor stem cell infusion.
  • Immunosuppressive therapies were discontinued when liver graft function returned to normal.
  • RESULTS: The procedure could be completed in the two patients.
  • A transient macrochimerism was observed in the first case, while no chimerism could be detected in the second.
  • Immunosuppression was discontinued, respectively 90 and 28 days, after liver transplantation, without subsequent rejection episode.
  • In the two cases, liver function remained normal for the study period.
  • Mixed lymphocyte cultures, performed after immunosuppression withdrawal, demonstrated donor specific hyporesponsiveness in the first case, but in a context of global hyporeactivity in the two patients.
  • The first patient died from tumor recurrence 370 days after liver transplantation.
  • The second patient is alive, 270 days after liver transplantation, but with a suspicion of tumor relapse as indicated by the reappearance of tumor marker in blood.
  • CONCLUSION: In the two cases, acceptance of HLA mismatched living-donor liver graft was obtained after non-myeloablative conditioning and donor stem cell infusion.
  • Improving the rate of immune reconstitution appears as a priority to reduce the risk of tumor recurrence in such patients.
  • [MeSH-major] HLA Antigens / immunology. Immunosuppression / methods. Liver Transplantation / immunology. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning / methods. Transplantation, Homologous / immunology
  • [MeSH-minor] Antilymphocyte Serum / therapeutic use. Antineoplastic Agents / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / surgery. Combined Modality Therapy. Cyclophosphamide / pharmacology. Cyclophosphamide / therapeutic use. Fatal Outcome. Histocompatibility. Humans. Immunosuppressive Agents / therapeutic use. Interleukin-2 / biosynthesis. Interleukin-2 / genetics. Liver Neoplasms / surgery. Living Donors. Male. Middle Aged. Neoplasm Recurrence, Local. RNA, Messenger / biosynthesis. Sirolimus / therapeutic use. T-Lymphocytes / immunology. T-Lymphocytes / transplantation

  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15380544.001).
  • [ISSN] 0966-3274
  • [Journal-full-title] Transplant immunology
  • [ISO-abbreviation] Transpl. Immunol.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Antineoplastic Agents; 0 / HLA Antigens; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / RNA, Messenger; 8N3DW7272P / Cyclophosphamide; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


20. Tanida T, Tanemura M, Kobayashi S, Wada H, Marubashi S, Eguchi H, Takeda Y, Umeshita H, Mori M, Doki Y, Nagano H: [A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2729-31
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection].
  • To cure intrahepatic cholangiocarcinoma (ICC), only a surgical resection is the potential treatment at present.
  • However, recurrence tumors in residual liver and/or distant organs even after curative surgery are commonly experienced in clinical course.
  • Unfortunately the potential treatment for this recurrent disease is not established at present.
  • Here, we report the prolonged survival case with recurrent ICC after hepatic resection followed by combined therapy of intrahepatic arterial infusion with CDDP and S-1 administration.
  • After that, liver tumor of 30 mm in diameter was detected in S1/8 by abdominal CT examination.
  • Subsequently, caudate lobectomy and partial resection of Segment 8 were performed under the diagnosis of Hepatocellular carcinoma in Osaka university hospital.
  • The pathological stage was T2N0M0, Stage II with moderately differentiated intrahepatic cholangiocarcinoma.
  • As the recurrence tumor was found in Segment 4 of residual liver, we started a treatment with intrahepatic arterial infusion with CDDP and S-1 administration, immediately.
  • These combined therapy displayed beneficial effects and a recurrent liver tumor was well controlled.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Drug Combinations. Female. Hepatic Artery. Humans. Infusions, Intra-Arterial. Neoplasm Recurrence, Local. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224694.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Azoulay D, Andreani P, Maggi U, Salloum C, Perdigao F, Sebagh M, Lemoine A, Adam R, Castaing D: Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience. Ann Surg; 2006 Jul;244(1):80-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience.
  • BACKGROUND: Liver tumors with inferior vena cava (IVC) involvement may require combined resection of the liver and IVC.
  • This approach, with its high surgical risks and poor long-term prognosis, was precluded until the development of neoadjuvant chemotherapy, portal vein embolization, reinforced vascular prostheses, and technical advances in liver transplantation.
  • Indications for resection were: liver metastases (n = 9), cholangiocarcinoma (n = 8), hepatocellular carcinoma (n = 2), other cancers (n = 3).
  • The liver resections carried out included 18 first, 3 second, and one third hepatectomy.
  • Resection concerned 1 to 6 liver segments (median = 5.0).
  • Vascular control was achieved by vascular exclusion of the liver preserving the caval flow (n = 1), standard vascular exclusion of the liver (n = 12), in situ cold perfusion of the liver (n = 9).
  • Ex situ surgery was not necessary in any case.
  • The IVC was reconstructed with a ringed Gore-Tex tube graft (n = 10), primarily (n = 8), or by caval plasty (n = 4).
  • RESULTS: One patient died (4.5%) due to catheter infection, 7 days after in situ cold perfusion with replacement of the vena cava.
  • In all but 1 case, the complications were transient and successfully controlled.
  • With median follow-up of 19 months, 10 patients died of tumor recurrence and eleven were alive with (n = 5) or without (n = 6) disease.
  • CONCLUSIONS: IVC resection and reconstruction combined with liver resection can be safely performed in selected patients.
  • The lack of alternative treatments and the spontaneous poor prognosis justify this approach, provided that surgery is carried out at a center specialized in both liver surgery and liver transplantation.
  • The development of adjuvant chemotherapy regimens is required to improve the long-term results of this salvage surgery.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / surgery. Vena Cava, Inferior / surgery
  • [MeSH-minor] Adult. Aged. Blood Vessel Prosthesis Implantation. Female. Humans. Intraoperative Complications. Male. Middle Aged. Neoplasm Invasiveness. Postoperative Complications. Vascular Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2001 Mar;192(3):412-7 [11245386.001]
  • [Cites] Liver Transpl. 2001 Apr;7(4):359-62 [11303297.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1455-60 [11677986.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2):168-82 [11951215.001]
  • [Cites] Surgery. 1991 Feb;109(2):208-13 [1846984.001]
  • [Cites] Urology. 1992 Mar;39(3):285-8 [1546426.001]
  • [Cites] Am J Surg. 1992 Apr;163(4):387-94 [1373044.001]
  • [Cites] Can J Surg. 1994 Feb;37(1):59-61 [8306222.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2049-53 [10615076.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] J Vasc Surg. 2000 Feb;31(2):270-81 [10664496.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):480-6 [10749607.001]
  • [Cites] Surgery. 2000 May;127(5):520-7 [10819060.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] J Am Coll Surg. 2002 Jun;194(6):842-5 [12081078.001]
  • [Cites] Arch Surg. 2002 Dec;137(12):1332-9; discussion 1340 [12470093.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):243-9 [12595053.001]
  • [Cites] Arch Surg. 2003 Jun;138(6):624-30; discussion 630-1 [12799333.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):871-83; discussion 883-4 [14631224.001]
  • [Cites] Surgery. 2003 Dec;134(6):989-93; discussion 993-4 [14668732.001]
  • [Cites] Ann Surg. 2004 May;239(5):712-9; discussion 719-21 [15082976.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S248-60 [15508091.001]
  • [Cites] Ann Surg. 1966 Feb;163(2):237-41 [4286023.001]
  • [Cites] Surg Gynecol Obstet. 1973 May;136(5):711-6 [4349727.001]
  • [Cites] Ann Surg. 1974 Oct;180(4):644-52 [4414545.001]
  • [Cites] Surg Gynecol Obstet. 1978 Nov;147(5):689-93 [715645.001]
  • [Cites] Surg Gynecol Obstet. 1980 Feb;150(2):208-14 [7352313.001]
  • [Cites] World J Surg. 1982 Jan;6(1):3-9 [7090393.001]
  • [Cites] Surgery. 1984 Mar;95(3):309-18 [6701787.001]
  • [Cites] Ann Surg. 1984 Oct;200(4):524-34 [6385876.001]
  • [Cites] J Vasc Surg. 1984 Nov;1(6):877-87 [6208388.001]
  • [Cites] Br J Surg. 1985 Jul;72(7):565-8 [2990629.001]
  • [Cites] Arch Surg. 1988 Aug;123(8):1021-2 [2969230.001]
  • [Cites] Acta Chir Scand. 1988 Jul-Aug;154(7-8):481-3 [2847455.001]
  • [Cites] Ann Surg. 1989 Jul;210(1):13-9 [2742411.001]
  • [Cites] J Vasc Surg. 1990 Sep;12(3):367-70 [2169006.001]
  • [Cites] Arch Surg. 1991 Jan;126(1):106-8 [1985628.001]
  • [Cites] J Am Coll Surg. 2000 Sep;191(3):244-50 [10989898.001]
  • [Cites] J Cardiothorac Vasc Anesth. 1994 Feb;8(1):58-60 [8167287.001]
  • [Cites] Surgery. 1994 Jun;115(6):740-4 [8197568.001]
  • [Cites] Br J Surg. 1994 Jun;81(6):845-6 [8044598.001]
  • [Cites] Arch Surg. 1995 Jul;130(7):793-7 [7611873.001]
  • [Cites] Br J Surg. 1995 Nov;82(11):1535-9 [8535812.001]
  • [Cites] Arch Surg. 1996 Apr;131(4):442-7 [8615734.001]
  • [Cites] Ann Surg. 1996 Aug;224(2):155-61 [8757378.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] Hepatology. 1996 Nov;24(5):1121-7 [8903386.001]
  • [Cites] Arch Surg. 1997 Oct;132(10):1104-9 [9336509.001]
  • [Cites] Liver Transpl Surg. 1996 Sep;2(5):354-61 [9346676.001]
  • [Cites] Eur J Surg Oncol. 1997 Dec;23(6):570-2 [9484935.001]
  • [Cites] Br J Surg. 1998 Apr;85(4):485-8 [9607528.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] Arch Surg. 1999 Jan;134(1):30-5 [9927127.001]
  • [Cites] Surg Today. 1999;29(1):67-70 [9934835.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1151-5 [10370683.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2532-40 [10375099.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):24-30 [10400032.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4 [15570210.001]
  • [Cites] J Am Coll Surg. 2005 Jan;200(1):57-63 [15631921.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):277-85 [15650638.001]
  • [Cites] Ann Surg. 2000 Nov;232(5):665-72 [11066138.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):777-85 [11088072.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):763-9 [11087642.001]
  • [Cites] J Am Coll Surg. 2001 Jan;192(1):137-41 [11192916.001]
  • [Cites] CA Cancer J Clin. 1999 Jul-Aug;49(4):231-55 [11198884.001]
  • [Cites] Ann Surg. 2001 Feb;233(2):242-9 [11176131.001]
  • [ErratumIn] Ann Surg. 2007 May;245(5):table of contents
  • (PMID = 16794392.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1570596
  •  go-up   go-down


22. Chen HW, Sheu JC, Lin WC, Tsang YM, Liu KL: Primary liver lymphoma in a patient with chronic hepatitis C. J Formos Med Assoc; 2006 Mar;105(3):242-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver lymphoma in a patient with chronic hepatitis C.
  • Primary liver lymphoma is a very rare disease and is frequently overlooked as a possible diagnosis.
  • We report the case of an asymptomatic middle-aged man with chronic hepatitis C who developed primary liver lymphoma (PLL).
  • A large solitary tumor in the left lobe of the liver was incidentally detected on routine ultrasound examination.
  • Imaging studies showed mixed iso- and hypoechogenicity with hypoechoic rim, hypodense in the pre-contrast phase and thick wall enhancement in the post-contrast phase on computed tomographic study, hypointensity on T1WI, and hyperintensity of the central portion and slightly higher intensity in the peripheral wall on T2WI.
  • These pictures were different from focal nodular hyperplasia, hepatocellular carcinoma, cholangiocarcinoma or metastases.
  • Atypical hepatectomy was performed and the pathology of the hepatic tumor revealed non-Hodgkin's lymphoma.
  • Systemic staging revealed no evidence of nodal or bone marrow involvement, so PLL was diagnosed.
  • There was no tumor recurrence more than 4 years after operation and chemotherapy.
  • PLL should be included in the differential diagnosis of solitary hepatic tumor in patients who are hepatitis C virus-positive, and who have atypical imaging and no known malignancy or elevated tumor marker levels.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520842.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


23. Morizono S, Fukutomi M, Yokota M, Iguchi H, Funakoshi A, Wakasugi H, Ikeda Y, Hachitanda Y: [A case of combined liver cell and bile duct carcinoma detected 6 years after interferon therapy for chronic hepatitis C, in spite of showing complete response]. Nihon Shokakibyo Gakkai Zasshi; 2002 May;99(5):505-10
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of combined liver cell and bile duct carcinoma detected 6 years after interferon therapy for chronic hepatitis C, in spite of showing complete response].
  • [MeSH-major] Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / pathology. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12048895.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha
  •  go-up   go-down






Advertisement